Lobectomy: 173 Real Stories

173 stories match lobectomy. 84 of them mention chemotherapy.

Cancer Stories

Tim, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Tim's Patient Story

Patient Info: Tim Monds, Male, 50s | Stage IV

Biomarkers: High PD-L1 expression

Metastatic Site: Other lung lobes / lung nodules

As of March 2024, Tim Monds was identified as a Stage IV lung cancer survivor involved in discussion of the PaCES early palliative-care project and broader lung cancer advocacy.

Lung Cancer Voices
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Lung cancer brain metastasis grew into a pre-existing meningioma

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: brain

Six months after lung surgery, a pathologically confirmed brain metastasis developed beside and partly infiltrated a pre-existing meningioma. It was surgically removed, and the patient declined radiochemotherapy afterward.

PubMed Central
OutcomeSetback / Progression
Ivy, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Ivy's Survivor Story

Patient Info: Ivy E., Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: elbow, cervical spine/neck, rib, pelvis; brain

As of January 2024, Ivy reported no evidence of disease 1 year after right upper lobectomy, after years of response to EGFR-targeted therapy for initially Stage IV lung cancer.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage IIIA breast cancer history with benign lipid pneumonia mimicking lung malignancy

Patient Info: Anonymized, Female, 40s | Stage III

Prior Stage IIIA breast cancer treatment was completed; a later suspicious lung lesion proved to be benign lipid pneumonia rather than recurrence or lung cancer, and she was asymptomatic 1 year after lobectomy with continued surveillance for new right-lung changes.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery — Case 1

Patient Info: Anonymized, Male, 70+

Biomarkers: MET exon 14 skipping mutation

The tumour shrank by 82%; surgery found 5% viable residual tumour and no involved lymph nodes, with postoperative stage ypT2aN0M0. He continued savolitinib without serious adverse effects.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery — Case 2

Patient Info: Anonymized, Female, 60s

Biomarkers: MET exon 14 skipping mutation; PD-L1 expression 75%

Savolitinib produced approximately 72% tumour shrinkage. Surgery found 30% viable residual tumour, negative lymph nodes and ypT1bN0M0 disease; she recovered without complications and continued savolitinib.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

HER2-positive metastatic lung cancer treated with trastuzumab deruxtecan (Enhertu)

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ERBB2/HER2 copy-number gain of at least 20 copies; TP53 C242fs; CDK12 copy-number gain; tumour mutational burden 3.2 mutations/Mb

Metastatic Site: lungs / multiple pulmonary nodules

Trastuzumab deruxtecan reduced the pulmonary nodules by more than 50% at 3 months and produced a documented response lasting 13.8 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage I Lung CancerLung Cancer

Rare lung sarcoma causing repeated collapsed lungs

Patient Info: Anonymized, Female | Stage I

Biomarkers: SS18-SSX2 fusion; CD99-positive; epithelial membrane antigen-positive; TLE1-positive; BCL-2-positive

She remained well under surveillance, with no evidence of disease on imaging at 3 years after definitive lobectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Long-term erlotinib treatment alongside worsening kidney vasculitis

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: bone

Bone metastases showed osteosclerotic change after erlotinib began, and the drug continued because he was benefiting from treatment despite worsening renal vasculitis.

PubMed Central
OutcomeResponding Well
Susan, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Non-Small Cell Lung Cancer: Susan's Survivor Story

Patient Info: Susan Taylor, Female, 70+

As of July 2021, Susan had localized non-small cell lung cancer removed by robotic left upper lobectomy with lymph node removal and had returned to normal activities within 3 weeks; no metastatic disease or systemic therapy was reported.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Lung CancerLung Cancer

Immunotherapy and surgery for adenosquamous lung cancer with brain metastases

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 positive; no actionable mutations on next-generation sequencing.

After chemotherapy, 19 cycles of pembrolizumab, and right middle lobectomy, she was off immunotherapy and under observation in remission.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pleomorphic Lung Cancer Progressed Despite Pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 TPS 80%-90%.

Metastatic Site: small intestine; pleura; abdominal subcutaneous tissue

The cancer did not respond to pembrolizumab, and he died four months after immunotherapy began.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung Squamous Cell CarcinomaLung Cancer

Lung Cancer Metastases to Both Kidneys Causing Kidney Failure

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: PD-L1 highly expressed

Metastatic Site: brain|bilateral kidneys|lungs

The cancer progressed in both kidneys and lungs despite treatment, causing dialysis-dependent kidney failure. He later developed severe respiratory illness and died 5 days after readmission.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung CancerLung Cancer

Primary pulmonary adenoid cystic carcinoma found with chronic lymphocytic leukaemia

Patient Info: Anonymized, Male, 50s

Biomarkers: Cytokeratin-positive; SMA-positive; p63-positive; TTF-1-negative; S100-negative; CK20-negative; CD56-negative.

Six months after adjuvant radiation, restaging CT showed treatment-related changes without local or metastatic recurrence.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

NRG1-Fusion Lung Cancer With a 24-Month Response to Afatinib

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRG1 fusion; KRAS/EGFR/ALK/ROS1/ERBB2 alterations not detected

Metastatic Site: left lung

Her cancer progressed during atezolizumab, and she died in May 2019.

PubMed Central
OutcomeIn Memory